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CMV-antibody-negative or leukocyte-reduced cellu-
lar blood products. The guidelines also recommend
that Toxoplasma-seropositive HIV-infected persons
who have a CD4+ lymphocyte count <100 cells/mL
received chemoprophylaxis against toxoplasmosis
(such chemoprophylaxis is generally accomplished
with anti-Pneumocystis carinii medication). Earlier
recommendations for chemoprophylaxis against
Pneumocystis carinii pneumonia and Mycobac-
terium avium complex disease have also been up-
dated.
In addition to disease-specific recommendations,
the guidelines include an overview article designed
to prioritize the recommendations for health care
providers. This article provides an approach to the
initial and follow-up evaluations of the HIV-infected
patient and also contains sections on HIV-infected
pregnant women and HIV-exposed/infected chil-
dren. The guidelines are followed by 15 background
articles, which provide the information on which the
recommendations were based and include research
priorities generated by the development of the pre-
vention recommendations.
The guidelines conclude with quality standards
and implementation steps on the most standard-of-
care recommendations, such as chemoprophylaxis
against Pneumocystis carinii pneumonia. This final
section provides a mechanism by which health care
facilities can assess their degree of compliance with
the recommendations, so that they can detect and
correct compliance-related problems.
 An abbreviated version of the USPHS/IDSA
Guidelines will be published in CDC’s Morbidity and
Mortality Weekly Report in July.
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Recommendations for a Regional
Strategy for the Prevention and
Control of Emerging Infectious
Diseases in the Americas
On June 14-15, 1995, a conference on “Combating
Emerging Infectious diseases: Challenges for the
Americas” was held at the Pan American Health
Organization (PAHO) Headquarters in Washington,
D.C. The meeting was designed to shape a regional
strategy for preventing and controlling emerging
infectious diseases that could pose serious threats
to the peoples of the Americas.
Participants, convened by PAHO, included top offi-
cials and infectious disease experts from that organi-
zation as well as the World Health Organization, the
U.S. Centers for Disease Control and Prevention, the
Canadian Laboratory Center for Disease Control, the
U.S. Department of Defense, and several Latin Ameri-
can and Caribbean countries.
This international group of experts noted that an
increasing number of new, emerging, and ree-
merging infectious diseases have been identified in
both developed and developing nations and that
these diseases threaten to increase in the near fu-
ture. They include human immunodeficiency vi-
rus/acquired immunodeficiency syndrome, which
emerged in the l980s and now affects some 16 mil-
lion people worldwide; and cholera, which returned
to the Western Hemisphere for the first time this
century in 1991 and has caused more than 1 million
cases and 9,000 deaths in the Americas. PAHO esti-
mates that it will take more than a decade and over
$200 billion to control the current pandemic of this
disease.
The experts concluded that both early warnings
of, and rapid responses to, infectious disease threats
are needed. The group made several major recom-
mendations to PAHO and its member states to im-
prove surveillance, research, and communications
in developing countries. They also issued more de-
tailed recommendations in the areas of antimicro-
bial resistance, outbreak control, and information
and communication. In addition, a plan of action is
forthcoming.
The group made the following recommendations
for PAHO and its member countries:
General Recommendations
· Develop and frequently update prioritized dis-
ease-specific guidelines for the prevention and
control of diseases that are emerging or ree-
merging, both at the public health and individual
levels. This should include biologic and behav-
ioral change measures and will require groups of
experts for each disease as well as communica-
tions experts. Diseases of interest include yellow
fever, dengue, antimicrobial-resistant organisms
(malaria, tuberculosis, and enteric diseases),
measles, polio, cholera and other foodborne and
waterborne diseases, viral hemorrhagic fevers,
plague, rabies and other zoonoses, and try-
panosomiasis and other vector-borne diseases.
· Identify points of contact in the field to receive
and transmit information in countries. These
contacts should include organizations and indi-
viduals outside the government.
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information to the general public.
· Develop plans to improve and make more effi-
cient two-way communication on reporting, con-
trol, and modification measures. This may
require contracting information management
specialists to identify and implement the most
efficient means.
· Make efficient use of the press, including radio,
television and newspapers, fliers, and other
methods to educate the public and the medical
community, with an eye toward social mobiliza-
tion of communities to fight emerging diseases.
This will require expertise in communications
and support to the countries in developing infor-
mation dissemination plans. Countries should
define populations at greatest risk and focus the
information and control measures in these popu-
lations.
· Define different approaches for educating the
public and the medical community.
· Focus efforts on intersectorial action, including
education of policy makers outside the health
community.
Antimicrobial Resistance
The expert group recommended that both PAHO
and its member countries, where applicable, do the
following:
· S e e k  w a y s  t o  r e d u c e  a v a i l a b i l i t y  o f  o v e r - t h e -
counter antimicrobial agents, including those
used in veterinary medicine; this will require
efforts beyond the health care community and
involve education and dissemination of informa-
tion to all sectors.
· Intensify assistance to the countries in develop-
ing rational drug policies.
· Monitor sensitivity to antibiotics in each country
to allow for optimum antibiotic use for individual
cases and to eliminate antibiotics with little
therapeutic value. Employ mechanisms such as
WHONET and PHLIS to centralize, analyze, and
distribute antimicrobial sensitivity data.
· Develop and distribute specific recommendations
to extend the useful life of antimicrobial drugs.
· Frequently revise the list of essential antimicro-
bials based on sensitivity data.
· Initiate educational campaigns on the cost-effec-
tiveness of rational drug use in hospitals.
· Initiate collaboration with the pharmaceutical
industry on rational drug use, standardized la-
bels and warnings, and ethical marketing strate-
gies.
Outbreak Control
The expert group endorsed the leadership role of
PAHO in developing and disseminating guidelines
for outbreak evaluation and control and recom-
mended that PAHO
· Make timely recommendations to coordinate re-
sponse to outbreaks or threats, including issues
related to travel advice, quarantine, and com-
merce.
· Develop policies and standard operating plans for
response to outbreaks at the regional and country
levels. Assist countries in developing national
outbreak response plans and assist in training
teams.
· Identify and list individuals and groups with dis-
ease-specific expertise, laboratories with disease-
specific diagnostic capabilities, and products,
including diagnostic reagents, drugs, and vac-
cines (both licensed and investigational prod-
ucts). Frequently update these lists.
· Establish a standard system for rapid procure-
ment of vaccines, reagents, insecticides and an-
timicrobial drugs for prompt response to
outbreaks.
· Establish information management and dissemi-
nation procedures for use during outbreaks, in-
cluding accurate and frequent release of
information to the press and public.
· Conduct formal evaluations of responses to each
outbreak and use the lessons learned to improve
responses to subsequent outbreaks.
Information and Communication
The experts recommended communicating with
high-level government officials and emphasizing to
them the importance of a basic public health infra-
structure—including improvements in water, sani-
tation, and social and economic conditions—in
preventing diseases. The group suggested dissemi-
nating more information about public health impli-
cations of development (such as deforestation, dam
construction, urbanization, and other measures)
and seeking effective interaction with other sectors.
Other Recommendations
PAHO should
· Create interagency task forces for emerging dis-
eases at regional and country levels.
· Inform regional governments, other organiza-
tions, and the public about the emerging disease
initiative and strive for the highest level of politi-
cal support.
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the emerging diseases initiative, both at the re-
gional and country levels. A portion of these funds
should be immediately available when outbreaks
are recognized.
For more information on these recommendations,
the conference, or its plan of action, contact PAHO.
Daniel B. Epstein
Office of Information & Public Affairs
Pan American Health Organization
Washington, D.C., USA
Tenth Annual ASTPHLD Conference
on Human Retrovirus Testing
The Tenth Annual Conference on Human
Retrovirus Testing, sponsored by the Association of
State and Territorial Public Health Laboratory Di-
rectors (ASTPHLD), was held March 6 to 9, 1995, in
Reno, Nevada. The conference, which was attended
by more than 300 representatives of public and
private sector laboratories as well as test kit manu-
facturers, emphasized three themes: new human
immunodeficiency virus (HIV) variants, interna-
tional issues, and HIV testing of newborns. The
topics discussed included sequence data for type O
isolates, the search for new HIV variants, zi-
dovudine (AZT) resistance, decreased maternal-neo-
natal transmission due to AZT prophylaxis, results
of the national anonymous survey of HIV prevalence
in the United States, and the ethical concerns of
perinatal screening.
An international perspective on HIV testing was
brought to the conference by presentations that fo-
cused on India and Latin America. Results were
given of a project, funded by a 12-month study grant
from the World AIDS Foundation, to provide train-
ing on HIV testing to laboratories in India. Four
Indian facilitators were trained in the United
States; they provided translation and other assis-
tance to eight ASTPHLD faculty, who gave work-
shops in four training centers in India. This
training, which focused on enzyme immunoassay,
linked trainees with staff from Indian reference
centers and established training materials and
trainers for future workshops to be conducted by
Indian staff.
Laboratory aspects of HIV testing in Latin Ameri-
can and the Caribbean were also discussed by a
member of the Pan American Health Organization
(PAHO), who described the spectrum of HIV inci-
dence rates and testing algorithms. PAHO is asking
countries of the region to assess their algorithms in
terms of sensitivity, specificity, and cost. PAHO aims
to support national laboratories by providing guide-
lines and quality assurance. Proficiency testing,
which is encouraged, will be provided by the Centers
for Disease Control and Prevention.
ASTPHLD’s 11th Annual Human Retrovirus
Conference is set for March 6-8, 1996, in Orlando,
Florida. Requests for additional information are
available; FAX request to 202-887-5098.
James L. Pearson
Division of Consolidated Laboratory Services,
Commonwealth of Virginia, Richmond, Virginia, USA
Emerging Infectious Diseases
Laboratory Fellowship Program
A partnership has been established between the
Association of State and Territorial Public Health
Laboratory Directors and the Centers for Disease
Control and Prevention (CDC) to develop and initi-
ate an emerging infectious diseases laboratory fel-
lowship program in January 1996. A goal of this
fellowship program is to strengthen local, state, and
federal public health infrastructures to support sur-
veillance and implement prevention and control pro-
grams. The fellowship program will help recruit and
train microbiologists for laboratories nationwide
and provide opportunities for doctoral level scien-
tists to conduct high-priority infectious disease re-
search.
The emerging infectious diseases fellowship pro-
gram will offer a 2-year laboratory research track
for doctoral level scientists, with emphasis on ap-
plied research or development in infectious diseases
and a 1-year advanced laboratory training track for
bachelor’s and master’s level scientists, with em-
phasis on the practical application of emerging in-
fectious diseases technologies, methods, and
practices. Fellow training and research will take
place at CDC and state and local public health
laboratories.
For applications or additional information, con-
tact
Emerging Infectious Diseases Fellowship
 Program
Association of State and Territorial Public
 Health  Laboratory  Directors
1211 Connecticut Avenue, Suite 608
Washington, D.C. 20036
Phone: 202-822-5227, Fax: 202-887-5098
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